AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01988155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric Exercise
Description: Subjects in the eccentric exercise group will be instructed to perform the modified Alfredson eccentric protocol for insertional Achilles tendinopathy. To perform the eccentric exercise, subjects will be instructed to stand upright with one hand on the wall or a chair for support as needed. A heel raise exercise is then performed with the non-painful leg. Once in the elevated position, subjects are instructed to transfer all of their body weight to the painful leg and slowly lower their heel to the floor while keeping their knee extended. The eccentric exercise program will consist of 3 sets of 15 repetitions performed per session. Subjects will perform 2 sessions per day for a total of 12 weeks and a log will be kept to monitor compliance. In order to partially control for the effect of regular contact with a therapist, subjects in the control group will be contacted by telephone one time per week to discuss their progress with the program and address any questions they may have.
Study NCT01988155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Astym
Description: In addition to performing the same eccentric protocol as the eccentric exercise group, subjects in the Astym group will also be seen in the clinic two times per week. Astym treatment will be performed per the foot, ankle, and knee protocol as described in the Astym clinical manual. During the first visit each week, the eccentric exercise protocol will be orally reviewed to match the one time per week phone education received by the eccentric only group. Astym treatment will continue for up to six weeks but may be discontinued early if a subject scores 90 or above on the VISA-A. Subjects in the Astym group will be required to continue with the eccentric exercise protocol for the full 12 weeks even in Astym is discontinued early.
Study NCT02578069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOVA Intracranial Sirolimus Eluting Stent System
Description: A sirolimus eluting intracranial stent system with polylactic-co-glycolic acid (PLGA) biodegradable drug carrier and electro-grated polybutyl methacrylate (PBMA) base coating. The stent platform is made of 316L stainless steel.
Study NCT02578069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apollo Intracranial Stent System
Description: A 316L stainless steel balloon-expandable intracranial stent system
Study NCT01062932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cycloserine
Description: Oral administration of cycloserine medication (50 mg administered prior to each exposure treatment) on Day 1, 4, 7, and 10 of the study
Study NCT01062932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of matching placebo pill on Days 1, 4, 7, and 10
Study NCT00653510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actrapid (human insulin)
Description: On day one the patients will receive glucose and insulin in order to reach a blood sugar around 18 and 20 mmol/L and on day two the patients will receive glucose and insulin in order to have a blood sugar around 5 and 7 mmol/L. On both days amino acid, lipid and glucose metabolism will be assessed by means of whole body isotope dilution.
Study NCT00400465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal dressing
Description: Normal dressing
Study NCT00400465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure dressing
Description: Pressure dressing
Study NCT03228550 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Efamol Active 50+
Description: 1000 mg docosahexaenoic acid, 160 mg eicosapentaenoic acid, 20 µg B12, 1 mg folic acid, 124 mg phosphatidylserine, 240 mg ginkgo biloba standardized leaf extract and 20 mg vitamin E
Study NCT03228550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Static exercise cycle
Study NCT03228550 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo multinutrient
Description: Placebo multinutrient supplement
Study NCT03755310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: First week: 10 mg tabs; Second week: 10-20 mg tabs
Study NCT03755310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent dosage, route of administration and dose regimen
Study NCT01919502 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Semi-quantitative urine pregnancy test
Study NCT03905018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tadalafil 20 MG
Description: tadalafil 20 mg orally ,after a single administration
Study NCT03905018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 MG
Description: tadalafil 20 mg orally ,after a single administration
Study NCT00907335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retin-A Micro 0.04% facial acne treatment
Description: Retin-A Micro 0.04% facial acne treatment used once daily
Study NCT00907335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control
Description: Color-matched facial gel vehicle control used once daily
Study NCT04232722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenicals
Description: As4 S4
Study NCT00424710 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ranibizumab intravitreal injection
Description: liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year
Study NCT02891499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: 1. Immediate post-operative period (implantation day) Red emission (660 nm) Energy density: 4 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 One application, 10 seconds of non-contact irradiation (01 point at the area surrounding the miniscrew) at a distance of 15,5 mm.~2. Mediate post-operative period (after implantation day) Infrared emission (808 nm) Energy density: 8 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 6 applications every 48 hours after the day of implantation, 20 seconds of non-contact irradiation (01 point on the area surrounding the miniscrew) at a distance of 15,5 mm.
Study NCT02891499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mediate force application
Description: Mediate force application protocol: orthodontic force application (150 gF) 4 weeks after the day of the implantation.
Study NCT01459211 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lenalidomide & Dexamethasone
Description: Subjects with relapsed or refractory CLL will receive twelve 28-day cycles of treatment. Each cycle will consist of:~1. Oral Dexamethasone (20mg daily, days 1-4),~2. Oral Lenalidomide on days 1-28 of each cycle, starting at 5mg per day in cycle 1 in patients with creatinine clearance ≥ 60ml/min calculated by Cockcroft-Gault. The dose will be increased to 10mg per day with cycles 2-12 unless there is evidence of disease progression or unacceptable drug toxicity
Study NCT04444726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra Violet A Device.+ Topical medical treatment
Description: Hands of the patient are irradiated in the UVA device after soaking for 20 minutes into 10 litres of water containing psoralen meladenine capsule.
Study NCT04444726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iontophoresis device + Topical medical treatment
Description: Tap-water iontophoresis was given 3 times weekly for 10 min. The direct current level was slowly increased, guided by the occurrence of tingling sensations. The maximum level was 30 mA.
Study NCT04444726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical medical treatment (Betamethasone dipropionate 0.05%  diprolene  )
Description: thin film of the cream is being applied to the affected areas for 2 times per day.
Study NCT04444726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical medical treatment (Betamethasone dipropionate 0.05%  diprolene  )
Description: thin film of the cream is being applied to the affected areas for 2 times per day.
Study NCT01128634 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK573719
Description: 13 days dosing with GSK573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
Study NCT01128634 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GW573719/GW573719
Description: 13 days dosing with GSK573719/GW573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
Study NCT01532596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: 8-week standardized mindfulness meditation training program
Study NCT01412502 — intervention group
Intervention type: OTHER
Intervention: IES-R and HDAS scores
Description: The Impact of Event Scale and Hospital Depression and Anxiety Score questionnaires are administered to participants.
Study NCT04683484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nanocovax
Description: Recombinant Protein spike (s) SARS-CoV-2 and adjuvant (0,5 mg Al PO4)
Study NCT04683484 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0,5 mg Al PO4
Study NCT01670084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Given PO
Study NCT01670084 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT01670084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01670084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT01670084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT01670084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV or IT
Study NCT01670084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or IT
Study NCT01670084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study NCT01670084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Description: Given IV
Study NCT01670084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV or PO
Study NCT01670084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01114698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine XR
Description: Venlafaxine XR 75 mg/day administered orally once daily as 2 capsules identical in appearance to JNJ26489112 during the first week increased to 150 mg/day during weeks 2 through 6.
Study NCT01114698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 2 capsules identical in appearance to JNJ26489112 and venlafaxine XR orally administered once daily for 6 weeks.
Study NCT01114698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ26489112
Description: JNJ26489112 500 mg/day orally administered once daily as 2 capsules for the first 3 weeks, then dose may be increased to 1000 mg/day by week 4.
Study NCT05182593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet moderate/high in FODMAPs
Description: The subjects will obtain meal boxes prepared in the hospital kitchen with a moderately high FODMAP content (23 grams/day)
Study NCT05182593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet low in FODMAPs
Description: The subjects will obtain meal boxes prepared in the hospital kitchen with a low FODMAP content (\<5 grams/day)
Study NCT00003475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Adults with a primary malignant brain tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT02556177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI scanning
Study NCT03697252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline and Trospium Chloride Capsules
Description: Xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-34 unless the subject is experiencing adverse events from the xanomeline 100 mg/trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/trospium 20 mg depending on clinical response and tolerability. Dosing must not change after Visit 7 of the study (at 21 ± 2 days of dosing) and may be decreased for tolerability reasons no more than once during the study.
Study NCT03697252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Placebo Capsules
Study NCT02531802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETVAX
Description: Varying dosages of liquid ETVAX vaccine (Batch BX1003574). A full dose consisted of:~* Hybrid protein between the B-subunit of the E. coli heat-labile enterotoxin and the B-subunit of the cholera toxin (LCTBA): 1 mg~* E. coli ETEX 21 formalin inactivated: 1.3 mg colonization factor 1 (CFA/I)~* E. coli ETEX 22 formalin inactivated: 6.4 mg coli surface antigen 3 (CS3)~* E. coli ETEX 23 formalin inactivated: 1.1 mg coli surface antigen 5 (CS5)~* E. coli ETEX 24 phenol inactivated: 0.5 mg coli surface antigen 6 (CS6)~The vaccine was given together with sodium bicarbonate effervescent granules (Recip), which was dissolved in water and mixed with the vaccine suspension prior to oral administration. The buffer was used to prevent degradation of LCTBA hybrid protein by the gastric acid.
Study NCT02531802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dmLT
Description: Varying dosages of dmLT, a derivative of wild-type enterotoxigenic Escherichia coli LT that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
Study NCT02531802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bicarbonate Buffer
Description: Sodium bicarbonate buffer dissolved in 150 ml of potable water
Study NCT02531802 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bicarbonate Buffer
Description: Sodium bicarbonate buffer dissolved in 150 ml of potable water
Study NCT01745939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Manipulation
Description: Manual therapy intervention
Study NCT01745939 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham manipulation
Description: Manual therapy intervention
Study NCT02889952 — intervention group
Intervention type: DEVICE
Intervention: Near infrared camera (NIR)
Description: Surgical field was examined with NIR, during a few minutes (\<5') with room lights switched off, to avoid parasite lights, then conventional open thyroidectomy was resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, were checked visually.~NIR consisted of a 750 nm class 1 laser excitation, with a power \<20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international norm IEC 60601-2-41). It was provided by the Fluobeam® camera, which was inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 1 device).
Study NCT01278225 — intervention group
Intervention type: BEHAVIORAL
Intervention: EEG biofeedback (BF) Group
Description: Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions.
Study NCT01278225 — intervention group
Intervention type: BEHAVIORAL
Intervention: Wait-List Control (WLC) Group
Description: Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits.
Study NCT01278225 — intervention group
Intervention type: BEHAVIORAL
Intervention: Follow UP Questionnaires
Description: After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
Study NCT04404413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensity interval training (HIIT)
Description: 2x8 weeks of high-intensity interval training (HIIT)
Study NCT04404413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensity interval training (HIIT) + intermittent fasting
Description: 2x8 high-intensity interval training with (HIIT+IF) intermittent fasting caloric restriction (20% reduction in weekly energy intake).
Study NCT03435250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-270
Description: AG-270, orally, once or twice daily, on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
Study NCT03435250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-270
Description: AG-270, orally, once or twice daily, for 1 week prior to the first dose of docetaxel. Thereafter, AG-270 continues to be given daily, on Days 1 through 21 of each 21-day cycle, until disease progression or unacceptable toxicity.
Study NCT03435250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-270
Description: AG-270, orally, once or twice daily for 1 week prior to the first doses of nab-paclitaxel and gemcitabine. Thereafter, AG-270 continues to be given daily on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
Study NCT03435250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel, IV, once during each 21-day cycle, until disease progression or unacceptable toxicity.
Study NCT03435250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Nab-paclitaxel, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
Study NCT03435250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
Study NCT02241616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir+Fuzheng Huayu+TCM Granule
Description: The subjects will be taking 1 Entecavir tablet per day, 4 Fuzheng Huayu tablets three times a day and specific Traditional Chinese Medicine granule for 48 weeks.
Study NCT02585856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDT
Description: Patients with unresectable CCA are performed PDT with ERCP after porfimer sodium （chongqing ray high medical instrument co., LTD，Chongqing, China) i.v. at a dose of 2 mg/kg at 48 h.~PDT procedure: for light distribution, flexible cylindrical diffuser probes mounted on 400-mm quartz fibres with an active distal tip length of 2 cm （chongqing ray high medical instrument co., LTD，Chongqing, China) is used. The light source was a diode laser system with a maximum power output of 2 Wand a wavelength of 633.3 nm. The power emitted by the diffuser tip was calibrated to 400 mW/cm before PDT was administered using an integrating sphere power meter. The mean irradiation time was 452 s (range: 400-600 s), using a power density of 300-400 mW/cm and an energy dose of 180-200 J/cm (of diffuser length).
Study NCT02585856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent
Description: Patients with unresectable CCA are performed with ERCP, one or several plastic biliary stents (Boston Scientific Corporation, MA,USA) are inserted to ensure adequate decompression and bile drainage.
Study NCT02585856 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: stent
Description: Patients with unresectable CCA are performed with ERCP, one or several plastic biliary stents (Boston Scientific Corporation, MA,USA) are inserted to ensure adequate decompression and bile drainage.
Study NCT00398554 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: involved field irradiation, single daily fractions 1,5 Gy to max. 1,8 Gy standard dose 20 Gy, max dose 30 Gy (boost irradiation if required)
Study NCT01719354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health center
Description: Observation of the functioning and coordination of health care before discharge to own home.
Study NCT01719354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: standard aftercare in hospital/mental health centers of District Psychiatric Service (DPS).
Study NCT01054170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 2 x 30 mg oral tablets twice daily (bid) for 12 weeks
Study NCT01054170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x matched placebo to oral tablet twice daily (bid) for 12 weeks
Study NCT00757341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-606
Study NCT03500601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nut components
Description: nut components consumed daily for a period of 28 days
Study NCT03500601 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consumed daily for a period of 28 days
Study NCT03945682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapist
Description: Intervention therapist at 2 centres providing 8 week intervention programme 50% embedded qualitative study